cagrisema phase 3 results 2025 cagrilintide semaglutide obesity Novo Nordisk's outperforms Ozempic in III trial Incretin-based therapies for the treatment
Incretin based therapies for the treatment of obesity related diseases npj Metabolic Health and Disease Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media CagriSema obesity drug: what the phase 3 data shows
Pay in 4 interest-free payments of $7.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12



